Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD

Autor: Cahn, A., Hamblin, J.N., Begg, M., Wilson, R., Dunsire, L., Sriskantharajah, S., Montembault, M., Leemereise, C.N., Galinanes-Garcia, L., Watz, H., Kirsten, A.M., Fuhr, R., Hessel, E.M.
Zdroj: In Pulmonary Pharmacology & Therapeutics October 2017 46:69-77
Databáze: ScienceDirect